Shulman DeMeo Asset Management’s AstraZeneca AZN Stock Holding History

Shulman DeMeo Asset Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-4,479	Closed	-$445K	–	70
2021 Q1	$445K	Buy	4,479 +1	+0%	+$101	0.12%	81
2020 Q4	$448K	Sell	4,478 -179	-4%	-$19K	0.13%	78
2020 Q3	$510K	Buy	4,657 +2	+0%	+$222	0.17%	58
2020 Q2	$492K	Hold	4,655	–	–	0.19%	54
2020 Q1	$416K	Sell	4,655 -884	-16%	-$83.2K	0.19%	52
2019 Q4	$552K	Sell	5,539 -10	-0.2%	-$941	0.19%	57
2019 Q3	$495K	Buy	5,549 +1,489	+37%	+$129K	0.17%	63
2019 Q2	$335K	Buy	4,060 +798	+24%	+$62.6K	0.12%	84
2019 Q1	$264K	Buy	+3,262	New	+$257K	0.1%	98

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Shulman DeMeo Asset Management's AZN Position: Q2 2021 in Review

Shulman DeMeo Asset Management sold out of AstraZeneca (AZN) in Q2 2021, closing a stake of 4,479 shares — an estimated $445K sold.

Shulman DeMeo Asset Management first reported a position in AZN in Q1 2019 and held it in 9 quarters. The position peaked at $552K in Q4 2019. 771 funds tracked by Wall St. Rank hold AZN as of Q2 2021.

Shulman DeMeo Asset Management reported no remaining AstraZeneca position as of Q2 2021 after selling out during the quarter.
Shulman DeMeo Asset Management sold 4,479 AstraZeneca shares in Q2 2021, an estimated $445K.
Shulman DeMeo Asset Management first reported a position in AstraZeneca in Q1 2019 and held it in 9 quarters.
Shulman DeMeo Asset Management's AstraZeneca position peaked at $552K in Q4 2019.
771 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2021.

Based on Shulman DeMeo Asset Management's 13F filing for Q2 2021, filed 21 Jul 2021.